UNSPSC 51410000: Vasodilators

This classification denotes drugs used to cause dilation of the blood vessels.

UNSPSC 51410000 Vasodilators is a Family code encompassing pharmaceutical products that state and local governments procure for emergency medical services, public health programs, and institutional healthcare operations. State and local solicitations under this code focus on specific vasodilator medications—such as Labetalol, Diltiazem, Adenosine, and Epinephrine—supplied as finished goods in standardized vial and injection formats, with strict expiration-date management, cold-chain delivery, and FDA compliance requirements. Issuing bodies include municipal fire-rescue departments, state health agencies, and multistate cooperative purchasing alliances. Solicitation structures range from sealed-bid competitive procurements for single jurisdictions to RFPs establishing tiered-wholesaler distribution networks spanning multiple states and member agencies.

The code shows recent activity concentrated in Florida and across multistate cooperative purchasing memberships including Minnesota and Oregon. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, seeking Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, and Diltiazem) for Tampa Fire Rescue with a response deadline of April 8, 2026 and an estimated contract value of $40,000, featuring a 5 percent Small Local Business Enterprise (SLBE) bid discount and one-year base contract with two optional one-year renewal periods. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, for Generic Multi Source Pharmaceuticals and OTC Products through three authorized wholesalers, with responses due March 26, 2026 and contract effectiveness July 1, 2026, requiring vendors to certify cGMP and Drug Supply Chain Security Act (DSCSA) compliance and maintain relationships with at least two of the three specified wholesalers. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, indicating early-stage planning for future formal procurement.